Newcastle University
Toggle Main Menu
Toggle Search
Home
Browse
Latest
Stats
Policies
About
Home
Browse
Latest
Policies
About
ePrints
Browsing publications by
Professor Herbie Newell
Newcastle Authors
Title
Year
Full text
Liz Matheson
Huw Thomas
Marian Case
Dr Helen Blair
Rosanna Jackson
et al.
Glucocorticoids and selumetinib are highly synergistic in RAS pathway mutated childhood acute lymphoblastic leukemia through upregulation of BIM
2019
Dr Catherine Drummond
Arman Esfandiari
Dr Xiaohong Lu
Dr Claire Hutton
Dr Jennifer Jackson
et al.
TP53
mutant
MDM2
-amplified cell lines selected for resistance to MDM2-p53 binding antagonists retain sensitivity to ionizing radiation
2016
Dr Gary Beale
Dr Emma Haagensen
Huw Thomas
Lan Wang
Charlotte Revill
et al.
Combined PI3K and CDK2 inhibition induces cell death and enhances
in vivo
anti-tumour activity in colorectal cancer
2016
Tristan Reuillon
Dr Sari Alhasan
Dr Gary Beale
Annalisa Bertoli
Alfie Brennan
et al.
Design and synthesis of biphenyl and biphenyl ether inhibitors of sulfatases
2016
Dr Emma Haagensen
Huw Thomas
Dr Ross Maxwell
Professor Herbie Newell
Enhanced anti-tumour activity of the combination of the novel MEK inhibitor WX-554 and the novel PI3K inhibitor WX-037
2016
Dr Rachel Pearson
Professor Peter Thelwall
Jim Snell
Dr Piotr Pieniazek
Professor Rakesh Heer
et al.
Evaluation of early responses to neoadjuvant chemotherapy in muscle-invasive bladder cancer using a dynamic contrast-enhanced MRI and diffusion-weighted MRI: MARBLE study
2016
Stephanie Myers
Dr Ruth Bawn
Betty Cottyn
Dr Lauren Molyneux
Dr Celine Cano
et al.
High-throughput screening and hit validation of extracellular-related kinase 5 (ERK5) inhibitors
2016
Dr Emma Haagensen
Huw Thomas
Dr Ross Maxwell
Professor Herbie Newell
Pre-clinical use of isogenic cell lines and tumours
in vitro
and
in vivo
for predictive biomarker discovery; impact of
KRAS
and
PI3KCA
mutation status on MEK inhibitor activity is model dependent
2016
Dr Sari Alhasan
Dr Beate Haugk
Laura Ogle
Dr Gary Beale
Anna Long
et al.
Sulfatase-2: a prognostic biomarker and candidate therapeutic target in patients with pancreatic ductal adenocarcinoma
2016
Lan Wang
Professor Herbie Newell
Professor Steve Wedge
Tumor cells with
KRAS
or
BRAF
mutations or
ERK5/MAPK7
amplification are not addicted to ERK5 activity for cell proliferation
2016
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
...